Causality assessment

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 325-343

  Lucena, Ma Isabel ^a   Andrade, Raoel J ^a   Camargo, Raquel ^a   García Cortés, Miren ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350242161     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. Bissel DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33(4):1009-13.
2. Nirenberg D. “Did this drug cause my patient’s hepatitis?" and related questions Ann Intern Med 2002; 136(6):480-3.
3. Meyboom RHB, Hekster YA, Egberts ACG, et al. Causal or casual? The role of causality assessment in Pharmacovigilance Drug Saf 1997; 17(6):374-89.
4. Kaplowitz N. Drug-induced liver disorders: introduction and overview. In: Kaplowitz N, Deleve LD, eds. Drug-Induced Liver Disease. New York: Marcel Dekker, Inc., 2003:1-14.
5. Maria VA, Victorino RM. Diagnostic value of specific T-cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997; 41(4):534-40.
6. Maria VA, Victorino RM. Immunological investigation in hepatic drug reactions. Clin Exp Allergy 1998; 28(Suppl. 4):71-7.
7. Zimmerman HJ. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
8. Berg PA, Becker EW. The lymphocyte transformation test: a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 1995; 22(1):115-8.
9. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4(6):489-99.
10. Andrade R, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129(2):512-21.
11. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity. Prevalence and clinicopathologic correlation among 104 patients. Hepatology 1989; 9(5):679-85.
12. Oien KA, Moffat D, Curry GW, et al. Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 1999; 353(9146):36-7.
13. Lewis JH, Schiff ER. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 88(12):1337-45.
14. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92(1):14-19.
15. Sturkenboom M, Meier CR, Jick H, et al. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999; 159(5):493-7.
16. Andrade RJ, Lucena MI, Alcantara R, et al. Bentazepam-associated chronic liver disease. Lancet 1994; 343(8901):860.
17. Andrade RJ, Lucena MI, Aguilar J, et al. Chronic liver injury related with the use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. Dig Dis Sci 2000; 45(7):1400-4.
18. Ishak KG, Zimmerman HJ. Hepatotoxic effects of anabolic androgenic steroids. Semin Liver Dis 1989; 7(3):230-9.
19. Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24(3):759-86.
20. Andrade RJ, Lucena MI, Fernández MC, et al. Hepatotoxicity in patients with cirrhosis, an often unrecognized problem. Lessons from a fatal case related with amoxicillin/clavulanic acid. Dig Dis Sci 2001; 46(7):1416-9.
21. Pérez-Moreno JM, Saldana FJ, Puertas M, et al. Cholestatic hepatitis caused by midecamycin. Gastroenterol Hepatol 1996; 19(9):459-61.
22. Lucena MI, Andrade RJ, Rodrigo L, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000; 30(2):400-1.
23. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38(Suppl. 2):S44-8.
24. Lucena MI, Andrade RJ, Vicioso L, et al. Prolongued cholestasis after raloxifene and fenofibrate interaction. World J Gastroenterol 2006; 12(32):5244-6.
25. Biour M, Poupon R, Grangé J-D, et al. Hépatotoxicitédes médicaments. 13e mise ájour du fichier bibliographique des atteintes hépatiques et des médicaments reponsables. Gastroenterol Clin Biol 2000; 24(11):1052-91.
26. Farrell GC. Drug Induced Liver Disease. London: Churchill-Livingstone, 1994.
27. Stricker BH. Drug-Induced Hepatic Injury. 2nd ed. Amsterdam: Elsevier, 1992.
28. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24(7):483-90.
29. Shah RR. Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React Toxicol Rev 1999; 18(4):181-233.
30. Watkins P, Withcomb R. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338(13):916-7.
31. Andrade RJ, Camargo R, Lucena MI, et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3(4):329-3444.
32. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000; 33(6):1003-5.
33. Relvas S, Carreira F, Castro B. Liver involvement in secondary syphilis. Am J Gastroenterol 1992; 87(10):1528.
34. Carrillo-Jiménez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis. Arch Intern Med 2000; 160(4):553-4.
35. Schattner A, Sokolovskaya N, Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J Intern Med 2000; 247(1):153-5.
36. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury:Long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44(6):1581-8.
37. Andrade RJ, Lucena MI, Martín-Vivaldi R, et al. Acute liver injury associated with the use of ebrotidine, a new H2- receptor antagonist. J Hepatol 1999; 31(4):641-6.
38. Bénichou C. Report of an International Consensus Meeting. Criteria of drug-induced liver disorders. J Hepatol 1990; 11(2):272-6.
39. Andrade RJ, Lucena MI, Fernandez C, et al. Cholestatic hepatitis related to use of irbesartan. A case report and a literature review of angiotensin II antagonists associated hepatotoxicity. Eur J Gastroenterol Hepatol 2002; 14(8):887-90.
40. Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M. Fatal hepatitis associated with nimesulide. J Hepatol 2000; 32(1):174.
41. Lucena MI, Andrade RJ, Gomez-outes A, et al. Acute liver failure after treatment with nefazodone. Dig Dis Sci 1999; 44(12):2577-9.
42. Goodman ZD. Drug hepatotoxicity. Clin Liver Dis 2002; 6(2):381-97.
43. Bianchi L. Liver biopsy in elevated liver function tests? An old question revisited. J Hepatol 2001; 35(2):290-4.
44. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32(Suppl. 1):77-88.
45. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15(2):244-51.
46. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44(5):731-5.
47. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349(5):474-85.
48. Lucena MI, Andrade RJ, Fernández MC, et al. Determinants of the clinical expression of amoxicillinclavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44(4):850-6.
49. Van Steenbergen W, Peeters P, De Bondt J, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998; 29(1):135-41.
50. Herrine SK, Keeffe EB. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130(2):163-4.
51. Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002; 47(7):1632-7.
52. Andrade RJ, Lucena MI. Drug-induced hepatotoxicity. N Engl J Med 2003; 349(20):1974-6.
53. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319(7224):1541.
54. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33(1):308-10.
55. Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol 1989; 42(1):5-16.
56. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4):315-21.
57. Pere JC, Begaud B, Haramburu F, et al. Computarized comparison of six adverse drug reaction assessment procedures. Clin Pharmacol Ther 1986; 40(4):451-61.
58. Karch FE, Lasagna L. Toward the operational identification of adverse drug reaction. Clin Pharmacol Ther 1977; 21(3):247-54.
59. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2):239-45.
60. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46(1):1323-30.
61. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46(11):1331-6.
62. Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26(3):664-9.
63. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33(1):123-30.
64. Aithal G, Rawlins M, Day C. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33(6):949-52.
65. García-Cortés M, Lucena MI, Andrade RJ, et al. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother 2004; 38(9):1540-1.
66. García-Cortes M, Lucena MI, Pachkoria K, et al. Evaluation of the Naranjo adverse drug reactions probability scale in the causality assessment of drug-induced liver injury. Am J Gastroenterol 2007 (submitted).
67. Takamori Y, Takikawa H, Kumagi T, et al. Assessment of the diagnostic scale for drug-induced liver injury by the international consensus meeting and a proposal of its modifications. Hepatology 2003; 38(4, Suppl. 1):703A.